NR1D1 and metabolic dysfunction-associated steatohepatitis: Intriguingly, a recent study elucidates the attenuation effect of systemic NR1D1 agonist administration on hepatic steatosis and inflammation in non-alcoholic steatohepatitis (NASH) mice might be attributed to the enhancement of gut barrier42.